Pyrowave
Pyrowave is a pioneer in the electrification of chemical processes based on low carbon footprint microwaves. Pyrowave is a leader in the plastics circular economy and chemical recycling. Its unique technology regenerates post-consumer and post-industrial plastics into new plastics, reclaiming these resources’ full value.
Sector
Industrial Biotech
Strategies
Status
Live
Website
www.pyrowave.com
Related News
Pyrowave Introduces Nanopurification Technology: A revolutionary short-loop chemical recycling innovation to remove toxic additives and contaminants in plastics
First finished products made with recycled styrene generated through Pyrowave technology
Michelin and Pyrowave Join Forces to Industrialize an Innovative Plastic Waste Recycling Technology
Pyrowave closes Series B led by Michelin and Sofinnova Partners
SofinnovaCapital
The Sofinnova Capital Strategy is our flagship fund, investing as founding or lead investor in early-stage biopharma and medtech start-ups developing groundbreaking therapeutic technologies.
SofinnovaMD Start
The Sofinnova MD Start Strategy is our in-house medtech accelerator focused on creating and launching early-stage medtech companies through hands-on company building.
SofinnovaCrossover
The Sofinnova Crossover Strategy invests in growth-stage biotech and medtech companies that have clinically validated their technologies and are preparing for commercialization.
SofinnovaIndustrial Biotech
Our Industrial Biotech Strategy invests in early-stage sustainable companies across the agriculture, chemicals, food and materials sectors.
SofinnovaTelethon
The Sofinnova Telethon Strategy makes early-stage investments in leading Italian science for the benefit of patients around the world.
SofinnovaDigital Medicine
Our Digital Medicine Strategy backs early-stage techbio and healthtech start-ups at the intersection of biology, data, and computation.
SofinnovaBiovelocita
The Sofinnova Biovelocita Strategy is our biotech accelerator, partnering with leading research organizations to create and build European biotech start-ups.